Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
The Oncologist · 2023
DOI: 10.1093/oncolo/oyac233 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Hiromichi Matsuoka und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Cancer Pain, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UMIN Clinical Trials Registry under registration no, Japan Agency for Medical Research and Development (Innovative Clinical Cancer Research:.
Abstract (Originalsprache)
Background
We hypothesized that the high-dose opioid requirement in patients carrying the rs4680-GG variant in the COMT gene encoding catechol-O-methyltransferase would be greater for patients taking morphine than for those taking oxycodone, thus providing a much-needed biomarker to inform opioid selection for cancer pain.
Methods
A randomized, multicenter, open-label trial was conducted at a Japanese hospital’s palliative care service. Patients with cancer pain treated with regular doses of nonsteroidal anti-inflammatory drugs or acetaminophen were enrolled and randomized (1:1) into morphine (group M) and oxycodone (group O) groups. The minimum standard dose of immediate-release (IR) oral opioids was repeatedly administered by palliative care physicians to achieve pain-reduction goals (Pain reduction ≥ 33% from baseline and up to ≤ 3 on a numerical rating scale). The primary endpoint was the proportion of subjects requiring high-dose opioids on day 0 with the GG genotype.
Results
Of 140 participants who developed cancer-related pain among 378 subjects registered and pre-screened for the genotype, 139 were evaluated in the current study. Among patients carrying a COMT rs4680-GG genotype, 48.3% required high-dose opioids in group M, compared with the 20.0% in group O (95% CI, 3.7%-50.8%; P = .029). Of those with the non-GG genotype, 41.5% treated with morphine and 23.1% with oxycodone required high-dose opioids (95% CI, 3.3%-38.3%; P = 0.098).
Conclusion
Using the COMT rs4680 genotype alone is not recommended for selecting between morphine and oxycodone for pain relief.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osaka, Japan.
- Palliative Care Center, Kindai Hospital, Osaka, Japan.
- Palliative Care Team, National Cancer Center, Tokyo, Japan.
- Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Biostatics, Kindai University Faculty of Medicine, Osaka, Japan.
ORCID-Profile: Hiromichi Matsuoka, Junji Tsurutani
Förderung
- UMIN Clinical Trials Registry under registration no
- Japan Agency for Medical Research and Development (Innovative Clinical Cancer Research:
Zitieren
APA
Matsuoka, H., Tsurutani, J., Chiba, Y., Fujita, Y., Sakai, K., Yoshida, T., Nakura, M., Sakamoto, R., Makimura, C., Ohtake, Y., Tanaka, K., Hayashi, H., Takeda, M., Okuno, T., Takegawa, N., Haratani, K., Koyama, A., Nishio, K., & Nakagawa, K. (2023). Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). The Oncologist. https://doi.org/10.1093/oncolo/oyac233
Vancouver
Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Sakai K, Yoshida T, et al. Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). The Oncologist. 2023. doi:10.1093/oncolo/oyac233
BibTeX
@article{Matsuoka2023,
author = {Matsuoka, Hiromichi and Tsurutani, Junji and Chiba, Yasutaka and Fujita, Yoshihiko and Sakai, Kiyohiro and Yoshida, Takeshi and Nakura, Miki and Sakamoto, Ryo and Makimura, Chihiro and Ohtake, Yoichi and Tanaka, Kaoru and Hayashi, Hidetoshi and Takeda, Masayuki and Okuno, Tatsuya and Takegawa, Naoki and Haratani, Koji and Koyama, Atsuko and Nishio, Kazuto and Nakagawa, Kazuhiko},
title = {Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyac233}
}
EUVIMED